Preventive Blood Tests: A Doctor’s Guide to Early Disease Detection

Introduction

Diagnostic blood testing broadly follows two patterns. Some conditions — including many cancers, autoimmune diseases, and infections — are typically investigated only once symptoms appear, as early detection without symptoms is often limited.

In contrast, many chronic conditions develop silently over years. Metabolic, cardiovascular, and thyroid disorders can often be identified earlier through routine blood testing, before they become clinically apparent.

These tests are widely available and part of everyday clinical practice — ones I interpret daily. For many patients, reviewing them every 1–2 years provides a practical way to track change over time.

Standard blood panels form a strong foundation, but an advanced blood panel — a small number of additional markers — can add meaningful resolution, helping to identify risk earlier through early disease detection.​​​​​​​​​​​​​​​​

Preventive Blood Tests: When an Advanced Panel Adds More

Routine blood work reliably detects established disease, monitors known conditions, and flags acute problems. This remains essential.

Where it can be extended is in the pre-clinical window — before values cross diagnostic thresholds. Type 2 diabetes, for example, is often diagnosed 4–7 years after the onset of hyperglycaemia [1], reflecting how risk develops gradually before reaching formal criteria.

Thyroid dysfunction is common in the general population [2], and cardiovascular risk has been extensively linked to underlying metabolic and inflammatory markers [5][9]. Standard panels provide a solid overview, but additional markers can help identify early changes — particularly in patients with borderline results or higher baseline risk.

In practice, this allows clinicians to recognise early metabolic, cardiovascular, and thyroid dysfunction before disease becomes clinically apparent.

The Metabolic Markers That Add Resolution

Glycated Haemoglobin HbA1c

Traditionally, the diagnosis of diabetes has relied on fasting glucose and oral glucose tolerance testing. More recently, HbA1c has been introduced as an additional diagnostic tool, complementing these measurements by adding a longer-term perspective on glucose regulation.

Glycated haemoglobin, or HbA1c, reflects average blood glucose levels over the preceding two to three months, providing a stable, time-averaged picture of glucose metabolism rather than a single snapshot influenced by recent factors such as diet [3].

An HbA1c of 5.7–6.4% indicates prediabetes; ≥6.5% indicates diabetes [3]. The clinically valuable insight is what sits below the diagnostic threshold: someone with an HbA1c of 5.8%, technically in the normal range, carries measurably elevated long-term risk. Elevated HbA1c has also been associated with increased cardiovascular risk and mortality even in people without diagnosed diabetes [3].

In the clinical settings I work in, HbA1c is routinely included in standard laboratory panels, and current diagnostic criteria allow diabetes to be diagnosed based on either an elevated fasting glucose or an elevated HbA1c when interpreted in the appropriate clinical context.

Fasting Insulin

Fasting insulin provides additional insight into earlier stages of metabolic dysfunction. As insulin resistance develops, insulin levels may rise for years before glucose becomes abnormal.

A meta-analysis of prospective cohort studies found that higher fasting insulin concentrations were significantly associated with increased risk of both hypertension and coronary heart disease, suggesting that fasting insulin measurement may help identify patients at elevated cardiovascular risk [4]. When both fasting glucose and fasting insulin are available, clinicians can calculate HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) — a widely used research and clinical index of insulin resistance — using the formula: fasting glucose (mmol/L) × fasting insulin (mIU/L) ÷ 22.5. This provides a practical picture of insulin sensitivity that neither marker delivers alone [4].

In my clinical work, fasting insulin is not routinely included in standard laboratory panels, but is used as a more targeted investigation to refine the clinical picture when insulin resistance is suspected, particularly in endocrinology-focused settings.

Refining Cardiovascular Risk: Triglycerides and ApoB

In my experience, lipid discussions often centre on total cholesterol and LDL, while triglycerides receive less attention — particularly when only mildly elevated — despite often reflecting underlying metabolic risk. This is also reflected in commonly used risk calculators, including those widely used in Finland, where triglycerides are not included as a core variable despite their close association with insulin resistance and metabolic risk.

Triglycerides

A systematic review and meta-analysis found that fasting hypertriglyceridaemia was significantly associated with cardiovascular death (odds ratio 1.80), cardiovascular events (OR 1.37), and myocardial infarction (OR 1.31) [5]. Elevated triglycerides frequently accompany insulin resistance and dyslipidaemia, and their presence alongside low HDL cholesterol is a pattern strongly predictive of metabolic syndrome.

While not targeted as directly with medication as LDL, triglycerides are often highly responsive to lifestyle interventions, with diet, weight, and physical activity having a meaningful impact on levels and overall cardiovascular risk.

Apolipoprotein B (ApoB)

The standard lipid panel remains a reliable starting point, but ApoB adds further precision by reflecting the number of atherogenic particles rather than cholesterol content alone.

A systematic review of 15 discordance studies involving 593,354 participants concluded that ApoB often provides a more accurate assessment of atherosclerotic cardiovascular disease risk than LDL, particularly when LDL and particle count are discordant [6]. Current guidelines from the European Society of Cardiology and the National Lipid Association support ApoB as a useful risk-refining marker — especially in patients with metabolic syndrome, elevated triglycerides, diabetes, obesity, or very low LDL [7].

ApoB is already included in some laboratory panels, but these tend to be newer and are not yet consistently adopted across all settings. In my experience, particularly in Finland, ApoB is still in the process of becoming more widely used, and clinicians are gradually becoming more familiar with its clinical value.

Thyroid: When to Go Beyond TSH

Subclinical hypothyroidism — defined as a TSH above the reference range with normal free T4 — affects up to 10% of the adult population and is more common in women [8]. It has been associated with increased risk of coronary artery disease events, heart failure, and cognitive impairment in middle-aged patients [8]. In patients with elevated TPO antibodies (markers of autoimmune thyroid disease), the risk of progression from subclinical to overt hypothyroidism is significantly higher.

TSH is already included in many routine panels and is often sufficient for initial assessment. However, in clinical practice, it is worth going a step further when TSH sits at the upper end of the reference range, or when patients present with nonspecific symptoms such as fatigue, weight gain, altered mood, or cognitive changes. 

TPO antibodies are often used intuitively in clinical practice when TSH or free T4 are clearly abnormal. However, they can also be useful in borderline cases, where results sit near the upper limit of normal or symptoms are nonspecific. In this context, TPO antibodies may help identify early autoimmune thyroid disease and add sensitivity to the assessment of subclinical hypothyroidism.

Inflammation: hsCRP as an Added Layer

High-sensitivity C-reactive protein (hsCRP) is a marker of low-grade systemic inflammation that is not typically included in standard panels but is straightforward to add. It is most useful as a complementary marker alongside lipids rather than a standalone screening tool.

A large population-based study in 448,653 UK Biobank participants without known cardiovascular disease found that individuals with hsCRP above 3 mg/L had a 34% higher risk of major adverse cardiovascular events, a 61% higher risk of cardiovascular death, and a 54% higher risk of all-cause death compared to those with hsCRP below 1 mg/L [9]. 

In that analysis, hsCRP added predictive value beyond conventional risk factors, with variable-importance analyses ranking it among the strongest predictors of cardiovascular events and death, in some models ahead of LDL [9].

High-sensitivity CRP (hsCRP) is also gradually finding its place in routine clinical practice. In newer laboratory panels — including those increasingly used in Finland — it is often already included, reflecting growing recognition of its role as a marker of low-grade inflammation and its contribution to cardiovascular risk assessment.

Preventive Blood Tests: The Bottom Line​​​​​​​​​​​​​​​​

Standard blood panels form a strong foundation, but an advanced blood panel — a small number of additional markers — can add meaningful resolution, helping to identify risk earlier through early disease detection.​​​​​​​​​​​​​​​​

In practice, markers such as HbA1c, fasting insulin, triglycerides interpreted in context, ApoB, TPO, and hsCRP are all accessible through standard laboratories and do not require specialist referral. These are tests I use regularly in clinical work to refine risk assessment and guide earlier intervention.

For patients who want to take a more proactive approach to their health, understanding which markers to follow — and how to interpret them over time — can make a meaningful difference in identifying risk before it becomes clinically apparent. For a more detailed breakdown of how these markers apply in an athletic and performance context, this clinical guide explores the overlap between preventive medicine and sport.